The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Everything is lining up very nicely. Richards body language was everything for me yesterday then you have Polygon adding furiously. Going only one way this and the countdown has truly began. Exciting times ahead and lives to be saved which makes the money part even better
Having just watched the Proactive Investor interview with RM yesterday on You Tube, he is so much more relaxed than his official delivery yesterday.
Chalk & cheese.
What did I pick up? Well he's confident it works but the 2 sticking blocks are that COVID stays around in the New Year and we get the buy in pending the data.
A lot of people on this board have been waiting for the data which of course is important, but also the need for the product of course is equally important.
Worth a watch.
Different person when he's relaxed
Been here since March 2020 with a healthy portfolio. I've followed the chat from a distance, good and bad and ive made infrequent comment.
The big question is realistically what are we looking at price wise in the near future?
We all know that highly likely that our hand will be finally shown pre-Xmas and whether it's good, average or bad will be seen very soon.
The big question is where have you set your stall at in regards to a target price before year end and getting out?
I know the potential, but I'm going for £6.50 on good results. We will then see a huge sell off and dips and rises.
What's your imminent target, as we are very close now?
Good luck all, we are getting close to the final result
Yes, pretty much sums it up in very simple terms..... phase 3 success and this will be huge
Synairgen (SNG.L) Shares Can Blow The Market After Releasing A Potential Treatment For Covid-19
June 29, 2021 Lora Nilsson
On June 1 the share price is 168.03 pounds. The next day it grows to 181.69 pounds, which is the highest price per month. The lowest price is 140.24 pounds on June 9. After that day, shares start growing up. On June 14 the price reaches 157.30 pounds. Consequently, shares keep going smoothly and there is no big difference in the price. Today it is 173.30 pounds.This year, the share price of Synairgen (LSE: SNG) has been on a rollercoaster. The stock is up 5.5 percent year to date. These figures, however, do not tell the whole story. The biotechnology company’s stock dropped by more than a third in May, from roughly 148p to a low of 98p. Following this low, the stock swiftly rebounded, surging higher over the following weeks to hit a high of 176p in early June.
Related: Below $5 Growing Stock: Kahoot! AS (OTC: KHOTF)
Synairgen’s main product might be lost if the treatment fails to pass the final testing stage. This would be a huge setback for the company, and the stock would definitely suffer as a result. If, on the other hand, the medication passes phase III trials, the company’s prospects are endless. SNG001 has so far been found to be effective against all types of respiratory viruses in testing. As a result, the market for this novel medicine might be enormous.
Yes it's hard to swallow and my portfolio is down £55,000 today with Synairgen, but it's only on paper.
I invested here because I have confidence and today wasnt a bad RNS, in fact I felt more secure about my investment that further evidence that the product works.
Best tip is to now switch off this board until next week...and enjoy the weekend.
It's not a loss or profit until you sell
https://youtu.be/BFFo7fhk-zM
For those doubting their investment then this 10 minute clip from October is well worth a watch to remind yourself about RMs confidence in the drug and this unique investment opportunity, that most of us are involved with.
The clock is ticking until results....
https://www.proactiveinvestors.co.uk/companies/news/939712/synairgen-richard-marsden-presents-updates-on-all-three-covid-19-treatment-trials-939712.html
It took me ages to go back to find it...so re posted for ease